gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · OPKHealthcarePharmaceuticals

Opko Health Inc. (OPK)

$1.69−4.47%
Close Nov 5, 2026 · split-adjusted
Nov 5, 2026$1.69▲ 21.64% in range
Nov 4, 2025Low $1.10 · High $1.77Nov 5, 2026
What changed · written from our data
As of Nov 5, 2026

Opko Health closed at $1.69 on Nov 5, down 4.47%, 4.5% below its 52-week closing high. Volume of 4.9M shares was 0.85× its 20-day average (close to normal).

Split-adjusted performance: +21.6% over one month, +51.0% over six months, +21.6% over one year.

In the quarter ended Jun 30, 2026, revenue was $163.58M, up 4.3% from a year earlier, with a net margin of -5.1%.

Short interest was 34.0M shares at the Oct 15 settlement, down 4.4% from the prior report (9.3% of float, 5.3 days to cover).

Market cap$1.26B746.3M shares
Revenue · quarter$163.6M+4.3% YoY
Diluted EPS$-0.01—
P/E · TTM—P/S 2.1×
Net margin-5.1%Gross 48.9%
Dividend yieldNone
52-week range1.10 – 1.77−4.5% from high
Volume4.9M0.85× 20-day avg
Volatility · 60d58.5%Annualised
Short % of float9.3%5.3 days to cover
Net cash-$46.5MCash $300.8M
Next earnings—Not scheduled
Split-adjusted performance
1W +1.9%1M +21.6%3M +23.4%6M +51.0%YTD +34.2%1Y +21.6%3Y +35.3%5Y −53.9%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 418 companies (100 = best)

6-month momentum94
Revenue growth46
Net margin66
Value (low P/E)—
Size73

Industry medians: 6-month return −27.4%, revenue growth +5.9%, net margin −37.5%, P/E 15.1×.

Short interest

Details →
Shares short34.0M−4.4% vs prior
Days to cover5.3Settled Oct 15
% of float9.3%
Short vol. 10d54.0%of daily volume

Closest peers by size in Pharmaceuticals

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
OPKOpko Health$1.69−4.47%+51.0%+4.3%−5.1%—$1.26B
LBRXLB Pharmaceuticals$38.74−5.18%+21.1%———$1.25BCompare
OMEROmeros$17.17−5.56%+17.3%—46.4%10.0$1.24BCompare
URGNUroGen Pharma$26.21−8.80%−1.4%+199.2%−19.8%—$1.29BCompare
NKTRNektar Therapeutics$36.01−6.42%−56.8%−9.3%−401.0%—$1.23BCompare
DMRADamora Therapeutics$21.32−7.08%————$1.32BCompare
KARDKardigan$14.10−9.42%————$1.32BCompare
MNKDMannkind$3.75−4.61%+5.6%+42.9%−17.4%—$1.21BCompare
AMPHAmphastar Pharmaceuticals$27.86−0.59%+15.9%+5.4%16.5%15.1$1.18BCompare

News about Opko Health

All news →
OPKO Health to Sell Select BioReference Assets to Labcorp for $722MZacks Investment Research · Oct 16, 2026▲ PositiveOPKO Health to Report Fourth Quarter 2025 Financial Results on February 26GlobeNewswire Inc. · Feb 12, 2026▲ Positive

Quick answers

What does Opko Health do?
OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Its segments include pharmaceutical and diagnostics.
What is OPK's market cap?
$1.26B, based on the Nov 5 close of $1.69.
Does Opko Health pay a dividend?
No regular cash dividend has been paid in the last year.
How much of OPK is sold short?
34.0M shares, 9.3% of float, as of Oct 15, 2026.
What sector is OPK in?
Healthcare, in the Pharmaceuticals industry.

About Opko Health

OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Its segments include pharmaceutical and diagnostics. The Pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its pharmaceutical research and development operations. The Diagnostics segment consists of clinical and genomics laboratory operations through BioReference and point-of-care operations. It generates the majority of its revenue from the Diagnostics segment.

HQ: Miami, FL2,275 employeesListed Nov 2, 1995opko.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology